Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT05918237 Completed - Clinical trials for Atopic Dermatitis Eczema

Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema

Start date: February 6, 2023
Phase: N/A
Study type: Interventional

Up to 30 participants with mild to moderate atopic dermatitis/eczema will be enrolled to apply study Investigational Product for 4 weeks.

NCT ID: NCT05916365 Active, not recruiting - Atopic Dermatitis Clinical Trials

Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

ADlong
Start date: May 23, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD). Participants who complete the last assessment visit in ADjoin (Week 100) will be offered the opportunity to enroll in this extension study.

NCT ID: NCT05913791 Active, not recruiting - Eczema Clinical Trials

Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema

Start date: March 6, 2023
Phase: N/A
Study type: Interventional

The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in individuals with eczema. It is hypothesised that daily consumption of nutrients-fortified egg, which is rich in antioxidants, will improve eczema conditions in individuals with eczema as compared to consumption of regular eggs.

NCT ID: NCT05911841 Recruiting - Atopic Dermatitis Clinical Trials

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Start date: June 21, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT05905133 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.

NCT ID: NCT05904509 Completed - Atopic Dermatitis Clinical Trials

Insulin Resistance in Atopic Dermatitis Patients

Start date: September 1, 2022
Phase:
Study type: Observational

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

NCT ID: NCT05899816 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

ROCKET-VOYAGER
Start date: June 7, 2023
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to: - estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 - estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24

NCT ID: NCT05891743 Recruiting - Dermatitis Clinical Trials

Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.

EPOXY
Start date: March 8, 2024
Phase:
Study type: Observational

The goal of this observational study it to learn about the prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry. The main question it aims to answer is: - What is the prevalence of skin sensitization and dermatitis among workers in the wind turbine industry who are exposed to epoxy? Participants will be asked to perform Patch Test, which is considered the Gold Standard test for identifying the cause of occupational contact allergic dermatitis. Researchers will compare the results of the epoxy-exposed group with those of a control group comprising non-exposed workers from the same industry. This analysis will help determine if there is a higher prevalence of skin sensitization among workers exposed to epoxy.

NCT ID: NCT05891119 Active, not recruiting - Atopic Dermatitis Clinical Trials

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Start date: June 3, 2023
Phase: Early Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).

NCT ID: NCT05882877 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

ROCKET-ASCEND
Start date: May 31, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.